Oct 2026· Cancers· Vol 18· 0 citations· 55 references
Medicine
TL;DR
Non-clear cell renal cell carcinomas comprise a heterogeneous group of kidney cancers with distinct biological features and clinical outcomes, and progress will depend on molecular stratification, subtype-specific trials, and integration of genomic and epigenomic insights to individualize prognosis and therapy.
Abstract
Simple Summary Non-clear cell renal cell carcinomas (nccRCCs) comprise a heterogeneous group of kidney cancers with distinct biological features and clinical outcomes. Prognosis varies substantially according to histology and molecular drivers. Historically, outcomes have been inferior to those of clear cell RCC because subtype-specific evidence has been limited. Immune checkpoint inhibitors, targeted agents, and combination strategies have improved response rates, but optimal management remains uncertain. Progress will depend on molecular stratification, subtype-specific trials, and integration of genomic and epigenomic insights to individualize prognosis and therapy.
This review evaluates biomarkers at three clinical decision points: characterization of an indeterminate renal mass; recurrence-risk assessment and adjuvant treatment selection after nephrectomy; and first-line regimen selection in metastatic ccRCC.
Hadi Al Etri, Lea Al Zoghby, Mohamad Sadek Zoghbi et al.· Genes· 0 citations
Current evidence for adjuvant, neoadjuvant, and perioperative systemic treatment for resectable non-small cell lung cancer is summarized and a practical approach to treatment selection is proposed.
Elio Nohra, T. Najdi, Axelle Serena El Karak et al.· Cancers· 0 citations
TFE3‐rearranged renal cell carcinoma (TFE3‐rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real‐world cohort.
Shu-Xuan Zhu, Si-Qi Zhou, Xi Tian et al.· Cancer Medicine· 0 citations
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with recurrence rates of 54–70% following curative-intent resection, even after microscopically complete (R0) surgery. In this review, we summarize the current evidence for adjuvant mitotane, platinum-based chemotherapy, and radiation therapy in resecte...
Lina Pedraza Sanchez, G. Rabinowits, Elio Monsour et al.· Cancers· 0 citations
Current FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers, including therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.
Augusto Almeida, Joao Manzi, Camila Hoff et al.· Translational Oncology· 1 citation
Endometrial cancers classified as having no specific molecular profile (NSMP) represent the most prevalent molecular subtype of the disease. In this review, we summarize the immunogenomic landscape and phenotypic features of NSMP endometrial cancer and discuss current and emerging therapeutic strategies, including endo...
Tarik Silk, U. Matulonis, Panagiotis A. Konstantinopoulos· Gynecologic Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
